UNASSIGNED: A 53-year-old man visited our hospital with a complaint of upper abdominal pain. Advanced CCA was diagnosed based on the biopsy of the metastatic lymph nodes and immunohistochemistry. Next-generation sequencing revealed MET amplification. As the patient was intolerant to traditional chemotherapy, savolitinib (a c-MET inhibitor) was administered. Partial response was achieved, and the treatment was well tolerated. After 1 year, the patient developed progressive disease, to which the emergence of epidermal growth factor receptor amplification may have contributed.
UNASSIGNED: Our study verified the therapeutic value of a c-MET inhibitor in advanced CCA-harboring MET amplification and provides an alternative strategy for patients who are intolerant to chemotherapy.
■一名53岁的男子主诉上腹痛到我院就诊。根据转移性淋巴结的活检和免疫组织化学诊断晚期CCA。下一代测序显示MET扩增。由于患者对传统化疗不耐受,给予savolitinib(c-MET抑制剂).取得了部分反应,治疗耐受性良好。一年后,病人发展为进行性疾病,表皮生长因子受体扩增的出现可能对此有贡献。
■我们的研究验证了c-MET抑制剂在晚期CCA-harordingMET扩增中的治疗价值,并为对化疗不耐受的患者提供了替代策略。